Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJ-40010 in healthy subjects
NCT04182932Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enterovirus 71 vaccine + coxsackievirus A16 vaccine in HIV-associated central nervous system involvement (HAND) (6 arms), sponsored by HK inno.N Corporation. Primary endpoint: Frequency and severity of adverse events of CJ-40010. Status: unknown.
02
Drugs
enterovirus 71 vaccine + coxsackievirus A16 vaccine
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT04182932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182932.